Novo Nordisk has named Greater Manchester as the 22nd city, and second in the UK, to join Cities Changing Diabetes, a scheme designed to address the dramatic rise of type II diabetes in urban areas.
Marking a UK-first, health and care leaders from Greater Manchester have formed a “pioneering partnership” with the pharmaceutical industry that aims to boost the care and treatment of people with dementia.